NCT04185415 - A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 3, 2019

Primary Completion Date

November 17, 2021

Study Completion Date

November 17, 2021

Conditions

Progressive Supranuclear Palsy

Interventions

DRUG

bepranemab

"bepranemab will be administered in a predefined dosage.~* Pharmaceutical Form: Solution for infusion~* Route of Administration: Intravenous"

DRUG

Placebo

"* Pharmaceutical Form: Solution for infusion~* Concentration: 0.9% w/v sodium chloride aqueous solution~* Route of Administration: Intravenous"

Trial Locations (13)

Psp003 40122, Edegem

Psp003 40002, Leuven

Psp003 40277, Bochum

Psp003 40276, Düsseldorf

Psp003 40278, Essen

Psp003 40024, Hanover

Psp003 40159, Barcelona

Psp003 40267, Barcelona

Psp003 40100, Madrid

Psp003 40268, Madrid

Psp003 40166, London

Psp003 40175, London

Psp003 40165, Southampton

All Listed Sponsors

lead

UCB Biopharma SRL

INDUSTRY